Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

An assessment of the genetic toxicology of novel boron-containing therapeutic agents.

Ciaravino V, Plattner J, Chanda S.

Environ Mol Mutagen. 2013 Jun;54(5):338-46. doi: 10.1002/em.21779. Epub 2013 Apr 26.

PMID:
23625818
2.

Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-year carcinogenicity studies.

Ciaravino V, Coronado D, Lanphear C, Shaikh I, Ruddock W, Chanda S.

Int J Toxicol. 2014 Sep-Oct;33(5):419-27. doi: 10.1177/1091581814545245. Epub 2014 Sep 7.

PMID:
25201897
3.

Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.

Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MR, Sanders V, Plattner JJ.

J Med Chem. 2006 Jul 27;49(15):4447-50.

PMID:
16854048
4.

Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2129-32. doi: 10.1016/j.bmcl.2009.03.007. Epub 2009 Mar 9.

PMID:
19303290
5.

Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.

Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, Lebwohl MG.

J Drugs Dermatol. 2016 Apr;15(4):390-6. Review.

PMID:
27050693
6.

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT.

J Drugs Dermatol. 2014 Sep;13(9):1124-32.

PMID:
25226015
7.

Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases.

Baker SJ, Akama T, Zhang YK, Sauro V, Pandit C, Singh R, Kully M, Khan J, Plattner JJ, Benkovic SJ, Lee V, Maples KR.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5963-7. Epub 2006 Sep 25.

PMID:
16997550
8.

AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.

Nazarian R, Weinberg JM.

Curr Opin Investig Drugs. 2009 Nov;10(11):1236-42. Review.

PMID:
19876791
9.

Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.

Gupta AK, Daigle D.

Expert Rev Anti Infect Ther. 2014 Jul;12(7):735-42. doi: 10.1586/14787210.2014.915738. Epub 2014 Jun 4. Review.

PMID:
24894552
10.

Potential role of tavaborole for the treatment of onychomycosis.

Gupta AK, Daigle D.

Future Microbiol. 2014;9(11):1243-50. doi: 10.2217/fmb.14.76.

PMID:
25437186
11.

An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.

Rock FL, Mao W, Yaremchuk A, Tukalo M, Crépin T, Zhou H, Zhang YK, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MR.

Science. 2007 Jun 22;316(5832):1759-61.

12.

Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles.

Seiradake E, Mao W, Hernandez V, Baker SJ, Plattner JJ, Alley MR, Cusack S.

J Mol Biol. 2009 Jul 10;390(2):196-207. doi: 10.1016/j.jmb.2009.04.073. Epub 2009 May 6.

PMID:
19426743
13.

Tavaborole for the treatment of onychomycosis.

Elewski BE, Tosti A.

Expert Opin Pharmacother. 2014 Jul;15(10):1439-48. doi: 10.1517/14656566.2014.921158. Epub 2014 May 26.

PMID:
24856836
14.
15.

Early rapid identification of in vivo rat metabolites of AN6414, a novel boron-containing PDE4 inhibitor by QTRAP LC/MS/MS to support drug discovery.

Bu W, Akama T, Chanda S, Sullivan D, Ciaravino V, Jarnagin K, Freund Y, Sanders V, Chen CW, Fan X, Heyman I, Liu L.

J Pharm Biomed Anal. 2012 Nov;70:344-53. doi: 10.1016/j.jpba.2012.05.024. Epub 2012 May 28.

PMID:
22687459
16.

Tavaborole: first global approval.

Markham A.

Drugs. 2014 Sep;74(13):1555-8. doi: 10.1007/s40265-014-0276-7.

PMID:
25118637
17.

Characterization of benzoxaborole-based antifungal resistance mutations demonstrates that editing depends on electrostatic stabilization of the leucyl-tRNA synthetase editing cap.

Sarkar J, Mao W, Lincecum TL Jr, Alley MR, Martinis SA.

FEBS Lett. 2011 Oct 3;585(19):2986-91. doi: 10.1016/j.febslet.2011.08.010. Epub 2011 Aug 16.

18.

Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase.

Hu QH, Liu RJ, Fang ZP, Zhang J, Ding YY, Tan M, Wang M, Pan W, Zhou HC, Wang ED.

Sci Rep. 2013;3:2475. doi: 10.1038/srep02475.

19.

Benzoxaborole antimalarial agents. Part 2: Discovery of fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.

Zhang YK, Plattner JJ, Freund YR, Easom EE, Zhou Y, Ye L, Zhou H, Waterson D, Gamo FJ, Sanz LM, Ge M, Li Z, Li L, Wang H, Cui H.

Bioorg Med Chem Lett. 2012 Feb 1;22(3):1299-307. doi: 10.1016/j.bmcl.2011.12.096. Epub 2011 Dec 28.

PMID:
22243961
20.

Tavaborole topical solution (Kerydin) for onychomycosis.

[No authors listed]

Med Lett Drugs Ther. 2015 Mar 2;57(1463):35-6. Review. No abstract available.

PMID:
25719999

Supplemental Content

Support Center